aglatimagene besadenovec
AXP000144.1 · Viral vector gene therapy
- Platform
- adenovirus (Ad5, E1-deleted, HSV-TK)
- Originator
- Advantagene
- Sponsor
- Candel Therapeutics
Names
| Name | Type | Source |
|---|---|---|
| aglatimagene besadenovec | preferred name, INN | curator, ncit |
| GliAtak | brand | ncit |
| ProstAtak | brand | ncit |
| Virafir | brand | ncit |
| ADV-tk ambiguous | code | ncit |
| CAN-2409 | code | ncit |
Virus
- Role
- In vivo gene transfer
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5
- Replication
- non replicating
- Modifications
- E1-deleted (replication-defective) adenoviral vector encoding HSV thymidine kinase; given with oral valacyclovir
- Transgenes
- HSV-TK
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C73996
- FDA UNII
- 5Z72SSS34W
Approvals
No regulatory approval recorded.
Clinical trials (13)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07660094 | Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA) | Recruiting | Phase 3 | 2026-06-15 | 2031-10-22 | 500 | Non-squamous, Non-Small Cell Lung Cancer |
| NCT07332000 | A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec | Recruiting | Phase 2 | 2025-10-30 | 2027-02 | 45 | Prostate Cancer (Adenocarcinoma); Prostate Cancer Patients Treated by Radiotherapy |
| NCT04495153 | CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC | Active not recruiting | Phase 2 | 2020-10-13 | 2024-12-31 | 90 | Non Small Cell Lung Cancer |
| NCT03576612 | GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas | Completed | Phase 1 | 2018-02-27 | 2023-06-30 | 41 | Glioma, Malignant |
| NCT03131037 | Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer | Completed | Phase 1 | 2017-05-04 | 2021-12-01 | 12 | Lung Cancer |
| NCT02768363 | Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) | Active not recruiting | Phase 2 | 2016-05 | 2024-11 | 187 | Prostate Cancer |
| NCT02446093 | Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma | Unknown | Phase 2 | 2015-10 | 2025-12 | 54 | Borderline Resectable Pancreatic Adenocarcinoma |
| NCT01997190 | Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion | Completed | Phase 1 | 2013-10 | 2015-12 | 19 | Breast Cancer; Lung Cancer; Malignant Pleural Effusion; Mesothelioma; Ovarian Cancer |
| NCT01436968 | Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer | Active not recruiting | Phase 3 | 2011-09 | 2024-08 | 711 | Prostate Cancer |
| NCT00634231 | A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors | Completed | Phase 1 | 2010-10 | 2015-12 | 8 | Malignant Glioma; Recurrent Ependymoma |
| NCT00638612 | AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01) | Completed | Phase 1 | 2008-08 | 2013-05 | 27 | Pancreatic Adenocarcinoma; Pancreatic Cancer |
| NCT00589875 | Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma | Completed | Phase 2 | 2007-03 | 2015-12 | 52 | Anaplastic Astrocytoma; Glioblastoma Multiforme; High Grade Glioma; Malignant Glioma |
| NCT00751270 | Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas | Completed | Phase 1 | 2005-11 | 2010-01 | 15 | Anaplastic Astrocytoma; Glioblastoma Multiforme; Malignant Glioma |
Unconfirmed matches (5)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT03541928 | Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery | Recruiting | Phase 2 | 2018-08-02 | 2023-07 | 60 | High-risk Prostate Cancer; Prostate Cancer | name in intervention: ADV-tk |
| NCT03313596 | Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC | Unknown | Phase 3 | 2013-03 | 2019-12 | 180 | Hepatocellular Carcinoma | intervention named: ADV-tk |
| NCT00870181 | ADV-TK Improves Outcome of Recurrent High-Grade Glioma | Completed | Phase 2 | 2008-01 | 2011-12 | 47 | Glioblastoma; Malignant Glioma of Brain | name in intervention: ADV-tk |
| NCT02202564 | Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma | Completed | Phase 2 | 2006-10 | 2011-10 | 81 | Hepatocellular Carcinoma; Liver Cancer | intervention named: ADV-tk |
| NCT00300521 | Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular Carcinoma | Completed | Phase 2 | 2000-09 | 40 | Hepatocellular Carcinoma; Liver Transplantation | name in intervention: ADV-tk |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42225101 | Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. | The Lancet. Oncology | 2026 | cited by trial NCT01436968 |
| PMID 42805763 | Prolonged survival after systemic immune reactivation by aglatimagene besadenovec plus valacyclovir in immune checkpoint inhibitor-refractory non-small cell lung cancer. | Journal for immunotherapy of cancer | 2026 | cited by trial NCT04495153 |
| PMID 40120123 | A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma. | Neuro-oncology | 2025 | cited by trial NCT03576612 |
| PMID 33160076 | Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity. | Molecular therapy : the journal of the American Society of Gene Therapy | 2021 | cited by trial NCT03131037 |
| PMID 30883662 | Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. | Neuro-oncology | 2019 | cited by trial NCT00634231 |
| PMID 29550074 | Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion. | Molecular therapy : the journal of the American Society of Gene Therapy | 2018 | cited by trial NCT01997190 |
| PMID 26843484 | Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. | Neuro-oncology | 2016 | cited by trial NCT00589875 |
| PMID 25795132 | Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. | Cancer immunology, immunotherapy : CII | 2015 | cited by trial NCT00638612 |
| PMID 21844505 | Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2011 | cited by trial NCT00751270 |
Unconfirmed matches (1)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 24052127 | Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer. | Cancer gene therapy | 2013 | name in title: ADV-tk |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39881590 | Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy. | Cancer research communications | 2025 | name in abstract: CAN-2409 |
| PMID 37228396 | Uncovering transcriptomic landscape alterations of CAN-2409 in in vitro and in vivo glioma models. | Frontiers in medicine | 2023 | name in title: CAN-2409 |
| PMID 35017150 | Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models. | Journal for immunotherapy of cancer | 2022 | name in abstract: CAN-2409 |
| PMID 36032633 | Perturbing DDR signaling enhances cytotoxic effects of local oncolytic virotherapy and modulates the immune environment in glioma. | Molecular therapy oncolytics | 2022 | name in abstract: CAN-2409 |
Unconfirmed matches (1)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 37542389 | Clinical Efficacy and Safety of AdV-tk Gene Therapy for Patients with Cervical Squamous Intraepithelial Lesion: A Prospective Study. | Human gene therapy | 2023 | name in title: ADV-tk |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| P01CA069246 | Project 3 Gene Mediated Cytotoxic Immmunotherapy for GBM | MASSACHUSETTS GENERAL HOSPITAL | CHIOCCA, E. ANTONIO | 2017–2021 | name in abstract: aglatimagene besadenovec |
| R44CA203336 | Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation | ADVANTAGENE, INC | AGUILAR-CORDOVA, ESTUARDO | 2016–2021 | name in abstract: aglatimagene besadenovec |
| R44CA124032 | Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer | ADVANTAGENE, INC | AGUILAR-CORDOVA, ESTUARDO | 2007–2013 | name in title: ProstAtak |
Unconfirmed matches (1)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R44CA107745 | Clinical study of AdV-tk radiogene therapy for malignant glioma | ADVANTAGENE, INC | AGUILAR-CORDOVA, ESTUARDO | 2004–2009 | name in title: ADV-tk |
Notes
CAN-2409: non-replicating Ad5 carrying herpes simplex virus thymidine kinase, injected into the tumour and followed by oral valacyclovir (the prodrug is a separate agent, not part of the program). Phase 3 in localised prostate cancer (ProstAtak) reported improved disease-free survival; also studied in glioma (GliAtak) and NSCLC. Virafir is a later brand name.
How to cite
aglatimagene besadenovec (AXP000144.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000144.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.